Daiichi Sankyo Company, Limited

Yuka Ashida

Makoto Ono

Masahiro Inoue

Tsutomu Nagata

Kengo Noguchi

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R, R, and Reach independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; Rrepresents a hydrogen atom or a prodrug group; and Y represents &#x2014;CH&#x2014;CHR&#x2014;CH&#x2014;NHR(wherein Rrepresents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and Rrepresents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

Growing community of inventors

Tokyo, Japan

Yuka Ashida